Additionally, CCRL2 targeting seems to have a therapeutic potential as CCRL2 modulates epigenetic regulatory pathways, particularly DNMT levels, and affects the sensitivity of MDS/secondary AML cells to azacitidine [89]. The gene discussed is CCRL2; the disease is acute myeloid leukemia.